The ongoing Phase Ib/IIa trial (NCT04146051) involving Descartes-08 rCAR-T cells for the treatment of generalized MG entailed transfecting mRNA-encoding anti-BCMA (B-cell maturation antigen) into CD8+ T cells. This evidence concerns the gene CD8A and myasthenia gravis.